EAM Investors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

EAM Investors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,323	Closed	-$1.98M	–	368
2014 Q3	$1.98M	Buy	+1,323	New	+$1.92M	0.4%	65
2014 Q2	–	Sell	-773	Closed	-$1.07M	–	373
2014 Q1	$1.07M	Buy	+773	New	+$899K	0.19%	285
2013 Q3	–	Sell	-1,307	Closed	-$1.43M	–	369
2013 Q2	$1.43M	Buy	+1,307	New	+$1.46M	0.31%	110

Other funds holding VIRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

EAM Investors's VIRX Position: Q4 2014 in Review

EAM Investors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 1,323 shares — an estimated $1.98M sold.

EAM Investors first reported a position in VIRX in Q2 2013 and held it in 3 quarters. The position peaked at $1.98M in Q3 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

EAM Investors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
EAM Investors sold 1,323 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $1.98M.
EAM Investors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 3 quarters.
EAM Investors's Viracta Therapeutics, Inc. Common Stock position peaked at $1.98M in Q3 2014.
78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on EAM Investors's 13F filing for Q4 2014, filed 9 Feb 2015.